Sotera Health (SHC)
Market Price (3/9/2026): $14.67 | Market Cap: $4.2 BilSector: Health Care | Industry: Health Care Services
Sotera Health (SHC)
Market Price (3/9/2026): $14.67Market Cap: $4.2 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 31% | Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -85% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 53x |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.2% | |
| Low stock price volatilityVol 12M is 43% | Key risksSHC key risks include [1] significant financial liabilities from extensive litigation and regulatory scrutiny over its ethylene oxide emissions and [2] a high debt load that limits financial flexibility. | |
| Megatrend and thematic driversMegatrends include Global Healthcare Product Safety & Compliance. Themes include Medical Device Sterilization, Biopharmaceutical Testing & Safety, and Advanced Diagnostics Support. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 31% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Low stock price volatilityVol 12M is 43% |
| Megatrend and thematic driversMegatrends include Global Healthcare Product Safety & Compliance. Themes include Medical Device Sterilization, Biopharmaceutical Testing & Safety, and Advanced Diagnostics Support. |
| Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -85% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 53x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.2% |
| Key risksSHC key risks include [1] significant financial liabilities from extensive litigation and regulatory scrutiny over its ethylene oxide emissions and [2] a high debt load that limits financial flexibility. |
Qualitative Assessment
AI Analysis | Feedback
Sotera Health (SHC) stock has lost about 15% since 11/30/2025 because of the following key factors:
1. Significant Insider/Private Equity Selling and Secondary Offering.
Major selling stockholders, including affiliates of Warburg Pincus LLC and GTCR LLC, announced a secondary offering of 25 million shares of common stock on March 4, 2026, from which Sotera Health will not receive any proceeds. The underwriter agreed to purchase these shares at $15.27 per share. This follows substantial insider selling in December 2025, where Warburg Pincus and GTCR collectively sold over 16 million shares at approximately $16.33 per share (totaling around $264.5 million). Additionally, CEO Michael Petras Jr. sold 750,000 shares for approximately $12.3 million on December 10, 2025. This significant divestment by key executives and large institutional holders likely signaled a lack of confidence or a strategic exit, putting downward pressure on the stock.
2. Cautious 2026 Outlook Amidst Persistent Regulatory and Litigation Risks.
Despite reporting its 20th consecutive year of revenue growth in 2025 and beating fourth-quarter 2025 earnings expectations with an EPS of $0.26 against a consensus of $0.24, Sotera Health's stock experienced declines of up to 7.1% following its 2026 guidance release on February 24, 2026. The outlook, projecting 2026 revenues of $1.233-$1.251 billion and Adjusted EPS of $0.93-$1.01, was perceived as "cautious" or "underwhelming" by investors. Management explicitly acknowledged ongoing legal and regulatory headwinds surrounding ethylene oxide (EO) sterilization facilities, indicating that these factors continue to influence the company's risk profile and necessitate elevated regulatory-driven spending.
Show more
1. Significant Insider/Private Equity Selling and Secondary Offering.
Major selling stockholders, including affiliates of Warburg Pincus LLC and GTCR LLC, announced a secondary offering of 25 million shares of common stock on March 4, 2026, from which Sotera Health will not receive any proceeds. The underwriter agreed to purchase these shares at $15.27 per share. This follows substantial insider selling in December 2025, where Warburg Pincus and GTCR collectively sold over 16 million shares at approximately $16.33 per share (totaling around $264.5 million). Additionally, CEO Michael Petras Jr. sold 750,000 shares for approximately $12.3 million on December 10, 2025. This significant divestment by key executives and large institutional holders likely signaled a lack of confidence or a strategic exit, putting downward pressure on the stock.
2. Cautious 2026 Outlook Amidst Persistent Regulatory and Litigation Risks.
Despite reporting its 20th consecutive year of revenue growth in 2025 and beating fourth-quarter 2025 earnings expectations with an EPS of $0.26 against a consensus of $0.24, Sotera Health's stock experienced declines of up to 7.1% following its 2026 guidance release on February 24, 2026. The outlook, projecting 2026 revenues of $1.233-$1.251 billion and Adjusted EPS of $0.93-$1.01, was perceived as "cautious" or "underwhelming" by investors. Management explicitly acknowledged ongoing legal and regulatory headwinds surrounding ethylene oxide (EO) sterilization facilities, indicating that these factors continue to influence the company's risk profile and necessitate elevated regulatory-driven spending.
Show more
Stock Movement Drivers
Fundamental Drivers
The -16.1% change in SHC stock from 11/30/2025 to 3/8/2026 was primarily driven by a -40.3% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.48 | 14.66 | -16.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,150 | 1,164 | 1.2% |
| Net Income Margin (%) | 4.8% | 6.7% | 39.0% |
| P/E Multiple | 89.6 | 53.5 | -40.3% |
| Shares Outstanding (Mil) | 284 | 284 | -0.1% |
| Cumulative Contribution | -16.1% |
Market Drivers
11/30/2025 to 3/8/2026| Return | Correlation | |
|---|---|---|
| SHC | -16.1% | |
| Market (SPY) | -1.6% | 42.4% |
| Sector (XLV) | -3.1% | 42.6% |
Fundamental Drivers
The -10.4% change in SHC stock from 8/31/2025 to 3/8/2026 was primarily driven by a -72.4% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.37 | 14.66 | -10.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,125 | 1,164 | 3.5% |
| Net Income Margin (%) | 2.1% | 6.7% | 213.6% |
| P/E Multiple | 193.5 | 53.5 | -72.4% |
| Shares Outstanding (Mil) | 284 | 284 | -0.1% |
| Cumulative Contribution | -10.4% |
Market Drivers
8/31/2025 to 3/8/2026| Return | Correlation | |
|---|---|---|
| SHC | -10.4% | |
| Market (SPY) | 4.5% | 41.9% |
| Sector (XLV) | 11.6% | 44.5% |
Fundamental Drivers
The 17.6% change in SHC stock from 2/28/2025 to 3/8/2026 was primarily driven by a 66.0% change in the company's Net Income Margin (%).| (LTM values as of) | 2282025 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.47 | 14.66 | 17.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,100 | 1,164 | 5.7% |
| Net Income Margin (%) | 4.0% | 6.7% | 66.0% |
| P/E Multiple | 79.6 | 53.5 | -32.8% |
| Shares Outstanding (Mil) | 283 | 284 | -0.4% |
| Cumulative Contribution | 17.6% |
Market Drivers
2/28/2025 to 3/8/2026| Return | Correlation | |
|---|---|---|
| SHC | 17.6% | |
| Market (SPY) | 14.2% | 54.5% |
| Sector (XLV) | 3.9% | 47.0% |
Fundamental Drivers
The -12.2% change in SHC stock from 2/28/2023 to 3/8/2026 was primarily driven by a -23.2% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.69 | 14.66 | -12.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,004 | 1,164 | 15.9% |
| P/S Multiple | 4.7 | 3.6 | -23.2% |
| Shares Outstanding (Mil) | 280 | 284 | -1.4% |
| Cumulative Contribution | -12.2% |
Market Drivers
2/28/2023 to 3/8/2026| Return | Correlation | |
|---|---|---|
| SHC | -12.2% | |
| Market (SPY) | 76.0% | 38.9% |
| Sector (XLV) | 25.7% | 36.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SHC Return | -14% | -65% | 102% | -19% | 29% | -15% | -45% |
| Peers Return | 46% | -25% | 4% | -4% | 16% | 1% | 28% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| SHC Win Rate | 50% | 33% | 50% | 50% | 58% | 33% | |
| Peers Win Rate | 73% | 40% | 44% | 46% | 55% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| SHC Max Drawdown | -24% | -75% | 0% | -36% | -28% | -15% | |
| Peers Max Drawdown | -3% | -37% | -17% | -18% | -12% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: STE, SOLV, CRL, LH, DGX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/6/2026 (YTD)
How Low Can It Go
| Event | SHC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -79.5% | -25.4% |
| % Gain to Breakeven | 387.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -9.3% | -33.9% |
| % Gain to Breakeven | 10.2% | 51.3% |
| Time to Breakeven | 59 days | 148 days |
Compare to STE, SOLV, CRL, LH, DGX
In The Past
Sotera Health's stock fell -79.5% during the 2022 Inflation Shock from a high on 3/12/2021. A -79.5% loss requires a 387.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sotera Health (SHC)
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Sotera Health (SHC) succinctly:
- The UL (Underwriters Laboratories) for medical device sterilization and testing, providing the critical services that ensure products are safe and compliant.
- The ADP for critical sterilization and safety testing services in the healthcare industry, handling an essential, outsourced regulatory-mandated process for manufacturers.
- The Amazon Web Services (AWS) for medical product safety infrastructure, providing essential sterilization and testing services that healthcare companies rely on to bring safe products to market.
AI Analysis | Feedback
- Sterilization Services: Provides contract sterilization for medical devices, pharmaceuticals, and other products utilizing gamma, E-beam, and ethylene oxide technologies.
- Laboratory Testing & Advisory Services: Offers microbiology and analytical chemistry testing, along with expert advisory services, primarily for the medical device and pharmaceutical industries.
- Cobalt-60: Supplies Cobalt-60 radioisotopes, which are essential for gamma sterilization processes and various medical applications.
AI Analysis | Feedback
Company: Sotera Health (SHC)
Sotera Health primarily sells its mission-critical sterilization, lab testing, and advisory services to other companies.
The company serves a highly diversified global customer base across several regulated industries, including:
- Medical Device Companies: Manufacturers of medical devices that require sterilization services and laboratory testing.
- Pharmaceutical Companies: Drug manufacturers that utilize sterilization services for products and packaging, as well as laboratory testing and advisory services.
- Food & Industrial Companies: Companies in the food and other industrial sectors that require specialized testing and sterilization services.
Due to the extensive and diversified nature of its customer base, Sotera Health does not have any single customer that accounts for 10% or more of its consolidated net revenues. As such, specific individual "major customers" are not identified by name in their public filings.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlMichael B. Petras Jr. Chief Executive Officer and Chairman
Mr. Petras has served as Sotera Health's Chief Executive Officer since June 2016 and as Chairman of its board since October 2020. Before joining Sotera Health, he was the Chief Executive Officer of Post-Acute Solutions at Cardinal Health, Inc. from 2015 to 2016, and Chief Executive Officer of Cardinal Health at-Home from 2013 to 2015. From 2011 to 2013, Mr. Petras was the Chief Executive Officer for AssuraMed Holdings, Inc., a medical products supplier that was owned by private equity firms Clayton, Dubilier & Rice and Goldman Sachs, and was subsequently sold to Cardinal Health, Inc. in 2013 for approximately $2 billion. He also spent over 20 years at General Electric, including serving as President and Chief Executive Officer at GE Lighting from 2008 to 2011.
Jonathan M. Lyons Senior Vice President and Chief Financial Officer
Mr. Lyons has served as Senior Vice President and Chief Financial Officer of Sotera Health since June 2023. Prior to this role, Mr. Lyons was the Vice President, Corporate FP&A for Owens Corning. He also served as Vice President and Finance Leader for Owens Corning's Insulation and Composites businesses, and previously as the company's Treasurer. Mr. Lyons held several senior leadership positions in treasury, FP&A, investor relations, and tax during an 8-year tenure at Cardinal Health.
Michael P. Rutz President of Sterigenics
Mr. Rutz has served as President of Sterigenics, a Sotera Health company, since October 2020, and as its Chief Operating Officer from May 2020 to October 2020. Before joining Sotera Health, he was Senior Vice President and General Manager of the Semiconductor Business Unit at Littlefuse, Inc., an electronic manufacturing company.
Joseph A. Shrawder President of Nelson Labs
Mr. Shrawder serves as President of Nelson Labs, a Sotera Health company. His previous experience includes leading GE Healthcare's Global Service business unit. He also served as CEO of GE Healthcare Latin America from January 2013 to July 2014, and as CEO of GE Healthcare's Surgery business unit from June 2010 to January 2013.
William O. Lehmann Jr. Senior Vice President of Strategy & Corporate Development
Mr. Lehmann serves as Senior Vice President of Strategy & Corporate Development at Sotera Health.
AI Analysis | Feedback
- Ethylene Oxide (EtO) Litigation and Regulatory Scrutiny: Sotera Health faces extensive litigation, with hundreds of personal injury claims and tort lawsuits alleging harm from ethylene oxide emissions from its Sterigenics facilities. These lawsuits have resulted in substantial jury verdicts and settlements, creating significant financial liabilities. The ongoing litigation also brings increased regulatory scrutiny of EtO emissions, which could lead to stricter environmental regulations and operational constraints.
- Dependence on Key Inputs: The company's sterilization processes heavily rely on critical materials such as ethylene oxide (EtO) and Cobalt-60 (Co-60). This dependence exposes Sotera Health to potential supply chain disruptions, price fluctuations, and geopolitical risks, which could adversely impact its cost structure and service delivery.
- Significant Leverage and High Debt: Sotera Health operates with significant leverage and a high debt load. This financial structure could limit the company's ability to raise additional capital, restrict its operational flexibility in responding to industry or economic challenges, and potentially hinder its capacity to meet existing debt obligations.
AI Analysis | Feedback
Intensifying regulatory scrutiny and proposed restrictions on Ethylene Oxide (ETO) sterilization, a critical service for Sotera Health's Sterigenics segment. Ongoing actions by the U.S. Environmental Protection Agency (EPA) and state regulators to tighten emissions standards and potentially limit the use of ETO pose a significant and evolving threat. This could lead to increased operational costs, potential facility disruptions, and necessitate a shift by medical device manufacturers towards alternative, potentially less efficient or more expensive, sterilization methods, impacting Sotera's market share and profitability within its largest business segment.
AI Analysis | Feedback
Sotera Health (SHC) operates in two primary addressable markets through its three business segments: sterilization services and lab testing and advisory services.
Sterilization Services
Sotera Health, through its Sterigenics and Nordion businesses, is a leading provider of sterilization services, including Ethylene Oxide (EtO), Gamma, and E-beam sterilization. Nordion specifically supplies Cobalt-60, a key component for gamma sterilization.
- The global sterilization services market was valued at approximately USD 3.52 billion in 2024 and is projected to reach USD 5.49 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.9%.
- Another estimate places the global sterilization services market at USD 3.93 billion in 2024, expecting it to increase to USD 7.93 billion by 2034 with a CAGR of 7.3%.
- In 2024, the global sterilization services market was also estimated at USD 5.60 billion, with projections to reach around USD 10.64 billion by 2034, demonstrating a CAGR of 6.63%.
- North America held the largest share of the global sterilization services market in 2024. The U.S. sterilization services market alone was valued at USD 1.75 billion in 2024 and is anticipated to reach approximately USD 3.38 billion by 2034, with a CAGR of 6.68%.
- The Ethylene Oxide (EtO) sterilization segment accounted for the largest share of the sterilization services market in 2024.
- The global gamma irradiation sterilization services market was estimated at USD 2.5 billion in 2025, with a projected CAGR of 7% from 2025 to 2033.
- The global medical device sterilization market was valued at USD 15.65 billion in 2025 and is projected to reach USD 28.93 billion by 2033, growing at a CAGR of 8.02%. The U.S. medical device sterilization market was valued at USD 5.09 billion in 2025 and is projected to reach USD 9.09 billion by 2033.
Lab Testing and Advisory Services
Through Nelson Labs, Sotera Health provides microbiological and analytical chemistry testing and advisory services primarily for the medical device and pharmaceutical industries.
- The global medical device testing market was valued at USD 5.20 billion in 2024 and is expected to reach USD 11.82 billion by 2032, at a CAGR of 10.80%.
- Another report indicates the global medical device testing services market was valued at USD 8.6 billion in 2024 and is expected to grow at a CAGR of 8.8% from 2025 to 2034.
- The global medical device testing services market size was estimated at USD 9.76 billion in 2024 and is projected to reach USD 16.77 billion by 2030, with a CAGR of 9.49%.
- North America dominates the global medical device testing market, accounting for approximately 40.2% of the market share in 2024, with the U.S. holding about 35%. However, Asia-Pacific dominated the medical device testing services market with a 41.18% share in 2024.
- The preclinical medical device testing services market is projected to expand from USD 1.7 billion in 2025 to USD 2.8 billion by 2035, at a CAGR of 5.3%. Medical device manufacturers are expected to account for 47% of this market in 2025.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Sotera Health (SHC)
- Favorable Pricing and Volume/Mix Expansion: Sotera Health consistently demonstrates pricing power across its segments, contributing to revenue growth. This is further bolstered by improvements in volume and mix across its Sterigenics and Nordion businesses, indicating increased demand and optimal utilization of services. For instance, Sterigenics' Q3 2024 revenue growth included favorable pricing of 4.4% and a 50 basis point increase from volume and mix. Similarly, Q1 2025 revenue growth for Sterigenics was driven by favorable pricing, while Nordion's growth was mainly attributable to volume and mix from the timing of reactor harvest schedules.
- Expansion within a Large Serviceable Addressable Market and Strategic Capital Investments: Sotera Health has identified a substantial serviceable addressable market of $18 billion, presenting significant opportunities for expansion. The company plans to leverage customer feedback to guide capital investment decisions and its growth outlook, aiming for an organic compound annual revenue growth rate of 5% to 7% for 2025-2027. This indicates a strategy of investing in capacity and capabilities to capture a larger share of its extensive market.
- Growth in Core Lab Testing Services and Stable Cobalt-60 Supply: Nelson Labs continues to see growth in its core lab testing services, which is a key driver for that segment. Furthermore, the Nordion segment benefits from the stability and strategic importance of its Cobalt-60 supply. The renewal of Nordion's Class 1B license for 25 years secures the global Cobalt-60 supply for sterilization and radiotherapeutic treatments, eliminating revenue risk associated with Cobalt-60 for 2025 and supporting mid- to high single-digit growth for the segment.
AI Analysis | Feedback
Share Issuance
- Sotera Health completed its initial public offering (IPO) in November 2020, generating approximately $1.1 billion in gross proceeds.
- The company executed a follow-on equity offering, issuing 20,000,000 shares of common stock at $15.35 per share, raising $307 million.
- An additional follow-on equity offering involved filing for 20,000,000 shares at $16.16 per share, valued at $323.2 million.
Inbound Investments
- The company raised approximately $1.1 billion in gross proceeds through its initial public offering in November 2020.
Capital Expenditures
- Capital expenditures were $54 million in 2020, $102 million in 2021, $182 million in 2022, $215 million in 2023, and $179.1 million in 2024.
- The capital expenditure guidance for 2025 has been revised downward multiple times, most recently to a range of $125 million to $135 million, citing project timing and cost savings.
- Expected capital expenditures for 2026 are approximately $110 million. These expenditures primarily focus on emissions controls, facility enhancements, regulatory compliance, and capacity expansion.
Latest Trefis Analyses
Trade Ideas
Select ideas related to SHC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
| 11302022 | SHC | Sotera Health | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 68.9% | 63.7% | -7.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 186.84 |
| Mkt Cap | 16.8 |
| Rev LTM | 7,077 |
| Op Inc LTM | 850 |
| FCF LTM | 718 |
| FCF 3Y Avg | 780 |
| CFO LTM | 1,002 |
| CFO 3Y Avg | 1,135 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.5% |
| Rev Chg 3Y Avg | 4.0% |
| Rev Chg Q | 5.1% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Mgn LTM | 12.5% |
| Op Mgn 3Y Avg | 13.6% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 17.7% |
| CFO/Rev 3Y Avg | 14.4% |
| FCF/Rev LTM | 12.6% |
| FCF/Rev 3Y Avg | 10.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 16.8 |
| P/S | 2.0 |
| P/EBIT | 15.2 |
| P/E | 23.6 |
| P/CFO | 14.0 |
| Total Yield | 4.6% |
| Dividend Yield | 0.5% |
| FCF Yield 3Y Avg | 4.5% |
| D/E | 0.3 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.1% |
| 3M Rtn | -8.8% |
| 6M Rtn | -3.6% |
| 12M Rtn | 3.9% |
| 3Y Rtn | 11.8% |
| 1M Excs Rtn | -8.8% |
| 3M Excs Rtn | -6.6% |
| 6M Excs Rtn | -6.5% |
| 12M Excs Rtn | -9.7% |
| 3Y Excs Rtn | -62.3% |
Price Behavior
Price Behavior
| Market Price | $14.66 | |
| Market Cap ($ Bil) | 4.2 | |
| First Trading Date | 11/20/2020 | |
| Distance from 52W High | -24.2% | |
| 50 Days | 200 Days | |
| DMA Price | $17.71 | $15.35 |
| DMA Trend | up | up |
| Distance from DMA | -17.2% | -4.5% |
| 3M | 1YR | |
| Volatility | 25.3% | 43.0% |
| Downside Capture | 123.32 | 107.04 |
| Upside Capture | 52.84 | 108.32 |
| Correlation (SPY) | 41.8% | 54.1% |
SHC Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.50 | 0.89 | 0.85 | 0.90 | 1.21 | 1.00 |
| Up Beta | 0.46 | 1.02 | 1.30 | 1.36 | 1.45 | 1.31 |
| Down Beta | 1.42 | 1.16 | 0.96 | 0.80 | 1.02 | 0.79 |
| Up Capture | -58% | 32% | 39% | 69% | 124% | 51% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 18 | 29 | 60 | 120 | 361 |
| Down Capture | 112% | 110% | 91% | 91% | 102% | 100% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 21 | 29 | 61 | 126 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SHC | |
|---|---|---|---|---|
| SHC | 26.8% | 42.9% | 0.66 | - |
| Sector ETF (XLV) | 3.4% | 17.5% | 0.04 | 47.4% |
| Equity (SPY) | 16.4% | 19.2% | 0.66 | 53.5% |
| Gold (GLD) | 77.1% | 26.1% | 2.17 | 8.1% |
| Commodities (DBC) | 19.6% | 17.1% | 0.89 | 18.4% |
| Real Estate (VNQ) | 3.1% | 16.6% | 0.01 | 40.9% |
| Bitcoin (BTCUSD) | -24.9% | 45.6% | -0.49 | 19.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SHC | |
|---|---|---|---|---|
| SHC | -11.5% | 65.1% | 0.03 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 26.9% |
| Equity (SPY) | 13.0% | 17.0% | 0.60 | 30.7% |
| Gold (GLD) | 24.2% | 17.2% | 1.14 | 5.5% |
| Commodities (DBC) | 11.9% | 19.0% | 0.51 | 7.6% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 26.7% |
| Bitcoin (BTCUSD) | 6.5% | 56.8% | 0.34 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SHC | |
|---|---|---|---|---|
| SHC | -5.0% | 64.1% | 0.06 | - |
| Sector ETF (XLV) | 10.4% | 16.5% | 0.52 | 26.8% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 30.8% |
| Gold (GLD) | 15.1% | 15.6% | 0.80 | 5.3% |
| Commodities (DBC) | 9.0% | 17.6% | 0.43 | 7.2% |
| Real Estate (VNQ) | 6.1% | 20.7% | 0.26 | 26.6% |
| Bitcoin (BTCUSD) | 65.9% | 66.8% | 1.05 | 11.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/24/2026 | -4.4% | -9.0% | |
| 11/4/2025 | -1.1% | -5.2% | -0.3% |
| 8/8/2025 | 24.5% | 40.5% | 41.8% |
| 5/1/2025 | 5.2% | 14.3% | 6.4% |
| 1/14/2025 | -2.5% | 1.7% | 2.3% |
| 11/5/2024 | -2.4% | 0.8% | -15.9% |
| 8/5/2024 | 7.6% | 10.1% | 16.2% |
| 2/27/2024 | 1.6% | -14.5% | -32.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 11 |
| # Negative | 10 | 10 | 7 |
| Median Positive | 1.7% | 7.5% | 6.4% |
| Median Negative | -4.6% | -9.3% | -12.8% |
| Max Positive | 24.5% | 40.5% | 41.8% |
| Max Negative | -10.8% | -14.5% | -32.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Petras, Michael B Jr | Chairman & CEO | Direct | Sell | 12102025 | 16.45 | 315,896 | 5,196,489 | 9,093,396 | Form |
| 2 | Petras, Michael B Jr | Chairman & CEO | Grantor Trust | Sell | 12102025 | 16.45 | 394,861 | 6,495,463 | 79,279,015 | Form |
| 3 | Petras, Michael B Jr | Chairman & CEO | Family Trust | Sell | 12102025 | 16.45 | 39,243 | Form | ||
| 4 | Warburg, Pincus & Co | See Footnote | Sell | 12052025 | 16.33 | 9,720,000 | 158,727,600 | 556,901,206 | Form | |
| 5 | Warburg, Pincus & Co | See Footnote | Sell | 12052025 | 16.33 | 9,720,000 | 158,727,600 | 556,901,206 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.